QCM
CRSP icon

Qsemble Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Qsemble Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-40,586
Closed -$2.13M – 475
2025
Q4 		$2.13M Buy
+40,586
New +$2.43M 0.18% 183
2025
Q3 		– Sell
-7,581
Closed -$369K – 486
2025
Q2 		$369K Buy
+7,581
New +$293K 0.04% 349
2025
Q1 		– Sell
-17,664
Closed -$695K – 462
2024
Q4 		$695K Buy
+17,664
New +$834K 0.09% 253

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Qsemble Capital Management's CRSP Position: Q1 2026 in Review

Qsemble Capital Management sold out of CRISPR Therapeutics (CRSP) in Q1 2026, closing a stake of 40,586 shares — an estimated $2.13M sold.

Qsemble Capital Management first reported a position in CRSP in Q4 2024 and held it in 3 quarters. The position peaked at $2.13M in Q4 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Qsemble Capital Management reported no remaining CRISPR Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Qsemble Capital Management sold 40,586 CRISPR Therapeutics shares in Q1 2026, an estimated $2.13M.
  • Qsemble Capital Management first reported a position in CRISPR Therapeutics in Q4 2024 and held it in 3 quarters.
  • Qsemble Capital Management's CRISPR Therapeutics position peaked at $2.13M in Q4 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Qsemble Capital Management's 13F filing for Q1 2026, filed 7 May 2026.